We are a biopharmaceutical company engaged in the development and commercialization of patented, differentiated and premium quality nutraceuticals and pharmaceuticals.
Blife Therapeutics intends to launch clinical trials to test the efficacy of IFNa2b for treatment of Covid 19. AP-003 is being developed as a novel interferon alpha2b (IFNa2b) inhalation formulation.
IFNa2b has been used to treat COVID 19 in China.²
Subject to receiving marketing authorization, AP-003 could potentially be used to treat patients early after COVID 19 infection which may potentially prevent the progression to severe disease and need for hospitalization.³
If successful in clinical trials, AP-003 may potentially be positioned as an initial treatment for COVID 19 and similar viruses.
For more information please see the full investor presentation.
- Subject to successful outcome of clinical trials and obtaining market authorization
- Dong et al, 2020; Lu, 2020; Shen & Yang, 2020; Zhou et al, 2020
- Altum Clin Protocol ALT 003 COV 01 2020 04 30
BetterLife has acquired worldwide rights for proprietary drug delivery technologies for commercialization of nutraceutical, pharmaceutical and wellness consumer products
MICELLE WATER SOLUBLE INGREDIENT DELIVERY SYSTEM FOR HIGH POTENCY.
1% CBD >99% PURE
READY FOR COMMERCIALIZATON
TECHNOLOGY FOR TRANFORMATION OF
CANNABINOID OIL TO POWDER
READY TO INFUSE CANNABINOID POWDER FOR USE IN CAPSULES, STICK PACKS, BULK POWDER, BEVERAGES, BAKED GOODS
Each technology platform allows BetterLife to produce multiple products
Better Life Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Our shares are publicly-traded on the CNX under the ticker symbol “BETR” and on the OTCQB under the ticker symbol “BETRF”
BLife Therapeutics Investor Presentation
Our Leadership Team